Shopping Cart 0
Cart Subtotal
USD 0

Merrimack Pharmaceuticals Inc (MACK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers. The company's marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (marketed chemotherapy drug) in a liposomal formulation used in the treatment of pancreatic metastatic adenocarcinoma. Its pipeline portfolio includes investigational candidates targeted at the treatment of advanced non-small cell lung cancer (NSCLC), solid tumors, metastatic breast cancer, and heregulin positive breast cancer. The company sells its products through a network of distributors in the US. Merrimack is headquartered in Cambridge, Massachusetts, the US.

Merrimack Pharmaceuticals Inc (MACK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Merrimack Pharma Amends Co-Development Agreement With Actavis 12

Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 13

Licensing Agreements 14

Merrimack Pharma Enters into Licensing Agreement with Ipsen 14

Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 15

Merrimack Pharma Amends Licensing Agreement with PharmaEngine for MM-398 17

Equity Offering 19

Merrimack Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 19

Merrimack Pharma Completes Public Offering Of Shares For USD 28.8 Million 20

Merrimack Pharma Completes IPO For USD 100 Million 22

Debt Offering 24

Merrimack Pharma Raises USD175 Million in Private Placement of 11.5% Notes Due 2022 24

Merrimack Pharma Completes Public Offering Of Notes Due 2020 For USD 125 Million 25

Asset Transactions 27

Ipsen Acquires Oncology Assets from Merrimack Pharma 27

Merrimack Pharmaceuticals Inc-Key Competitors 29

Merrimack Pharmaceuticals Inc-Key Employees 30

Merrimack Pharmaceuticals Inc-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Financial Announcements 32

Nov 07, 2018: Merrimack reports third quarter 2018 financial results and provides strategic update following portfolio review 32

Aug 07, 2018: Merrimack reports second quarter 2018 financial results 34

May 08, 2018: Merrimack Reports First Quarter 2018 Financial Results 36

Mar 12, 2018: Merrimack Reports 2017 Financial Results 37

Nov 08, 2017: Merrimack Reports Third Quarter 2017 Financial Results 39

Aug 09, 2017: Merrimack Reports Second Quarter 2017 Financial Results 40

May 10, 2017: Merrimack Reports First Quarter 2017 Financial Results 41

Mar 01, 2017: Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results 43

Corporate Communications 45

Feb 20, 2018: Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology 45

Nov 30, 2017: Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors 46

Aug 14, 2017: Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer 47

Jun 08, 2017: Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources 48

May 25, 2017: Merrimack Announces Management Change 49

Jan 18, 2017: Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO 50

Clinical Trials 51

Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 51

Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting 52

Mar 27, 2017: Merrimack to Present Data on MM-151 at the 2017 American Association for Cancer Research Annual Meeting 53

Mar 27, 2017: Merrimack to Present Data on MM-161 at the 2017 American Association for Cancer Research Annual Meeting 54

Mar 27, 2017: Merrimack to Present Data on MM-310 at the 2017 American Association for Cancer Research Annual Meeting 55

Mar 23, 2017: Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors 56

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Merrimack Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Merrimack Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Merrimack Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Merrimack Pharma Amends Co-Development Agreement With Actavis 12

Merrimack Pharma Enters Into Co-Development Agreement With Cancer Treatment Centers of America 13

Merrimack Pharma Enters into Licensing Agreement with Ipsen 14

Baxter International Enters into Licensing Agreement with Merrimack Pharma for MM-398 15

Merrimack Pharma Amends Licensing Agreement with PharmaEngine for MM-398 17

Merrimack Pharma Plans to Raise up to USD40 Million in Public Offering of Shares 19

Merrimack Pharma Completes Public Offering Of Shares For USD 28.8 Million 20

Merrimack Pharma Completes IPO For USD 100 Million 22

Merrimack Pharma Raises USD175 Million in Private Placement of 11.5% Notes Due 2022 24

Merrimack Pharma Completes Public Offering Of Notes Due 2020 For USD 125 Million 25

Ipsen Acquires Oncology Assets from Merrimack Pharma 27

Merrimack Pharmaceuticals Inc, Key Competitors 29

Merrimack Pharmaceuticals Inc, Key Employees 30

Merrimack Pharmaceuticals Inc, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Merrimack Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.